Literature DB >> 26461425

The non-toxigenic Clostridium difficile CD37 protects mice against infection with a BI/NAP1/027 type of C. difficile strain.

Keshan Zhang1, Song Zhao2, Yuankai Wang3, Xuejun Zhu4, Hong Shen4, Yugen Chen4, Xingmin Sun5.   

Abstract

Clostridium difficile CD37, a clinical isolate from the USA, does not produce toxin A, B or binary toxin. The aim of this study was to determine whether strain CD37 can protect mice against infection from a challenge with a toxigenic C. difficile strain. Three groups of mice (n = 10) were pretreated with a antibiotics cocktail for 5 days, switched to sterile water for 2 days, and given one dose of clindamycin (10 mg/kg) one day (day-1) before challenge (day 0) with a toxigenic C. difficile strain. Group 1 (CD37 + UK6) was given 10(7)C. difficile CD37 vegetative cells by gavage twice a day on days -1 and -2, followed by challenge with 10(6) spores of the toxigenic C. difficile UK6 (BI/NAPI/027) on day 0; Group 2 (UK6) was infected with 10(6)C. difficile UK6 spores on day 0; Group 3 (CD37) was challenged with 10(6) CD37 vegetative cells on day 0. Our data show that pre-inoculation of strain CD37 provided mice significant protection (survival, p < 0.001 between groups CD37 + UK6 and UK6) against subsequent infection with the strain UK6, while mice infected with CD37 only did not develop any symptoms of C. difficile infection (CDI). Our results highlight the potential use of CD37 as a therapeutic strain for the prevention of primary and recurrent CDI in humans.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26461425      PMCID: PMC4663165          DOI: 10.1016/j.anaerobe.2015.09.009

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  32 in total

1.  Refinement of the hamster model of Clostridium difficile disease.

Authors:  Gillian Douce; David Goulding
Journal:  Methods Mol Biol       Date:  2010

2.  Clospore: a liquid medium for producing high titers of semi-purified spores of Clostridium difficile.

Authors:  Justo Perez; V Susan Springthorpe; Syed A Sattar
Journal:  J AOAC Int       Date:  2011 Mar-Apr       Impact factor: 1.913

3.  Mouse relapse model of Clostridium difficile infection.

Authors:  Xingmin Sun; Haiying Wang; Yongrong Zhang; Kevin Chen; Barbara Davis; Hanping Feng
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

4.  Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters.

Authors:  R Fekety; J Silva; R Toshniwal; M Allo; J Armstrong; R Browne; J Ebright; G Rifkin
Journal:  Rev Infect Dis       Date:  1979 Mar-Apr

5.  Prevention of porcine Clostridium difficile-associated disease by competitive exclusion with nontoxigenic organisms.

Authors:  J Glenn Songer; Randy Jones; Michael A Anderson; Angelique J Barbara; Karen W Post; Hien T Trinh
Journal:  Vet Microbiol       Date:  2007-04-08       Impact factor: 3.293

6.  Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing.

Authors:  George Killgore; Angela Thompson; Stuart Johnson; Jon Brazier; Ed Kuijper; Jacques Pepin; Eric H Frost; Paul Savelkoul; Brad Nicholson; Renate J van den Berg; Haru Kato; Susan P Sambol; Walter Zukowski; Christopher Woods; Brandi Limbago; Dale N Gerding; L Clifford McDonald
Journal:  J Clin Microbiol       Date:  2007-11-26       Impact factor: 5.948

7.  Clindamycin-associated enterocolitis in guinea pigs: evidence for a bacterial toxin.

Authors:  F C Knoop
Journal:  Infect Immun       Date:  1979-01       Impact factor: 3.441

8.  A mouse model of Clostridium difficile-associated disease.

Authors:  Xinhua Chen; Kianoosh Katchar; Jeffrey D Goldsmith; Nanda Nanthakumar; Adam Cheknis; Dale N Gerding; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-09-10       Impact factor: 22.682

Review 9.  Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Authors:  Maja Rupnik; Mark H Wilcox; Dale N Gerding
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

10.  Piglet models of acute or chronic Clostridium difficile illness.

Authors:  Jennifer Steele; Hanping Feng; Nicola Parry; Saul Tzipori
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

View more
  9 in total

Review 1.  Primary Prevention of Clostridium difficile-Associated Diarrhea: Current Controversies and Future Tools.

Authors:  Zachary A Rubin; Elise M Martin; Paul Allyn
Journal:  Curr Infect Dis Rep       Date:  2018-06-29       Impact factor: 3.725

2.  Type IV Pili Promote Clostridium difficile Adherence and Persistence in a Mouse Model of Infection.

Authors:  Robert W McKee; Naira Aleksanyan; Elizabeth M Garrett; Rita Tamayo
Journal:  Infect Immun       Date:  2018-04-23       Impact factor: 3.441

Review 3.  Clostridioides difficile phage biology and application.

Authors:  Joshua Heuler; Louis-Charles Fortier; Xingmin Sun
Journal:  FEMS Microbiol Rev       Date:  2021-09-08       Impact factor: 16.408

4.  Antibiotic Treatments for Clostridium difficile Infection Are Associated with Distinct Bacterial and Fungal Community Structures.

Authors:  Regina Lamendella; Justin R Wright; Jada Hackman; Christopher McLimans; David R Toole; William Bernard Rubio; Rebecca Drucker; Hoi Tong Wong; Kate Sabey; John P Hegarty; David B Stewart
Journal:  mSphere       Date:  2018-01-10       Impact factor: 4.389

Review 5.  Advances in the diagnosis and treatment of Clostridium difficile infections.

Authors:  Zhong Peng; Lifen Ling; Charles W Stratton; Chunhui Li; Christopher R Polage; Bin Wu; Yi-Wei Tang
Journal:  Emerg Microbes Infect       Date:  2018-02-07       Impact factor: 7.163

Review 6.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

Review 7.  Clostridioides difficile infection and One Health: an equine perspective.

Authors:  Natasza M R Hain-Saunders; Daniel R Knight; Mieghan Bruce; Thomas V Riley
Journal:  Environ Microbiol       Date:  2022-01-21       Impact factor: 5.476

8.  Clostridium difficile ribotypes in humans and animals in Brazil.

Authors:  Rodrigo Otávio Silveira Silva; Maja Rupnik; Amanda Nádia Diniz; Eduardo Garcia Vilela; Francisco Carlos Faria Lobato
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-12-11       Impact factor: 2.743

9.  A Novel Bacteriophage Lysin-Human Defensin Fusion Protein Is Effective in Treatment of Clostridioides difficile Infection in Mice.

Authors:  Zhong Peng; Shaohui Wang; Mussie Gide; Duolong Zhu; Hiran Malinda Lamabadu Warnakulasuriya Patabendige; Chunhui Li; Jianfeng Cai; Xingmin Sun
Journal:  Front Microbiol       Date:  2019-01-11       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.